Work

Supplementary table 3 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma

Year: 2024

Type: supplementary-materials

Abstract: Supplementary table 3: Adverse Events/toxicities felt to be at least possibly related to drug.

DOI: 10.1158/2767-9764.25869054

Authors: Elizabeth I. Buchbinder, Justine V. Cohen, Giuseppe Tarantino, Christine G. Lian, David Liu, Rizwan Haq, F. Stephen Hodi, Donald P. Lawrence, Anita Giobbie-Hurder, Deborah Knoerzer, Ryan J. Sullivan

Language: English

Topic: Ocular Oncology and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4398175671

Cites:

Cited by:

Related to: 10